163 related articles for article (PubMed ID: 32968136)
1. A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma.
Yuan Y; Song JX; Zhang MN; Yuan BS
Sci Rep; 2020 Sep; 10(1):15497. PubMed ID: 32968136
[TBL] [Abstract][Full Text] [Related]
2. A new therapeutic combination for osteosarcoma: Gemcitabine and Clofazimine co-loaded liposomal formulation.
Caliskan Y; Dalgic AD; Gerekci S; Gulec EA; Tezcaner A; Ozen C; Keskin D
Int J Pharm; 2019 Feb; 557():97-104. PubMed ID: 30586631
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma.
Sun L; Zhou DS; Zhang P; Li QH; Liu P
Int J Pharm; 2015 Jan; 478(1):308-317. PubMed ID: 25433201
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management.
Kushwah V; Katiyar SS; Dora CP; Kumar Agrawal A; Lamprou DA; Gupta RC; Jain S
Acta Biomater; 2018 Jun; 73():424-436. PubMed ID: 29649635
[TBL] [Abstract][Full Text] [Related]
5. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
Li Y; Hou H; Zhang P; Zhang Z
Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
[TBL] [Abstract][Full Text] [Related]
7. Local release of gemcitabine via in situ UV-crosslinked lipid-strengthened hydrogel for inhibiting osteosarcoma.
Wu W; Dai Y; Liu H; Cheng R; Ni Q; Ye T; Cui W
Drug Deliv; 2018 Nov; 25(1):1642-1651. PubMed ID: 30799654
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Budman DR; Calabro A
Oncology; 2006; 70(2):147-53. PubMed ID: 16645328
[TBL] [Abstract][Full Text] [Related]
9. Decoration of Squalenoyl-Gemcitabine Nanoparticles with Squalenyl-Hydroxybisphosphonate for the Treatment of Bone Tumors.
Rodríguez-Nogales C; Desmaële D; Sebastián V; Couvreur P; Blanco-Prieto MJ
ChemMedChem; 2021 Dec; 16(24):3730-3738. PubMed ID: 34581019
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital.
Gosiengfiao Y; Reichek J; Woodman J; Ben-Ami T; Walterhouse D
J Pediatr Hematol Oncol; 2012 Mar; 34(2):e63-5. PubMed ID: 22217487
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma.
Chen B; Yang JZ; Wang LF; Zhang YJ; Lin XJ
BMC Cancer; 2015 Oct; 15():752. PubMed ID: 26486165
[TBL] [Abstract][Full Text] [Related]
12. pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo.
Xiao X; Liu Y; Guo M; Fei W; Zheng H; Zhang R; Zhang Y; Wei Y; Zheng G; Li F
J Biomater Appl; 2016 Jul; 31(1):23-35. PubMed ID: 27059495
[TBL] [Abstract][Full Text] [Related]
13. Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-κB pathway.
Liang C; Li H; Shen C; Lai J; Shi Z; Liu B; Tao HM
Anticancer Agents Med Chem; 2012 Jun; 12(5):554-63. PubMed ID: 22263786
[TBL] [Abstract][Full Text] [Related]
14. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
Qiu R; Sun D; Bai Y; Li J; Wang L
Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J
Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328
[TBL] [Abstract][Full Text] [Related]
16. Ceramic core with polymer corona hybrid nanocarrier for the treatment of osteosarcoma with co-delivery of protein and anti-cancer drug.
Prasad SR; Kumar TSS; Jayakrishnan A
Nanotechnology; 2018 Jan; 29(1):015101. PubMed ID: 29130895
[TBL] [Abstract][Full Text] [Related]
17. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma.
Susa M; Iyer AK; Ryu K; Hornicek FJ; Mankin H; Amiji MM; Duan Z
BMC Cancer; 2009 Nov; 9():399. PubMed ID: 19917123
[TBL] [Abstract][Full Text] [Related]
19. Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine.
Santiago T; DeVaux RS; Kurzatkowska K; Espinal R; Herschkowitz JI; Hepel M
Int J Nanomedicine; 2017; 12():7763-7776. PubMed ID: 29123391
[TBL] [Abstract][Full Text] [Related]
20. Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways.
Wang Y; Wang S; Liu J; Lu Y; Li D
Chem Biol Interact; 2018 Jun; 290():44-51. PubMed ID: 29782821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
